ACT offers important potential NASA commercial applications, as well as a significant return on NASA's SBIR investment. Techshot expects to commercialize the ACT by incorporating it into the company's spaceflight service program that it offers to NASA mission programs, as well as for other Government agencies such as investigators funded by the National Institute of Health's Biomed-ISS program. ACT provides an innovative tool for transferring liquid samples from unique experiment specific spaceflight hardware to on-orbit analytical tools, thus enabling real-time analysis on ISS. Both physics and life science investigators can expect to benefit from ACT since it can safely transfer, store and manipulate a host of fluid media to enable both processing and analysis of samples. Overall, the science research community will be better served with increased capacity of getting more samples processed and analyzed in space, and NASA will be one step closer to realizing its goal of fully utilizing ISS as a national laboratory. Building on its heritage of developing and integrating space flight hardware, and then conducting experiments in space, Techshot expects to soon offer flight experiment services to non-NASA customers, including the private sector and university researchers. The success of Techshot's processing facilities like the Avian Development Facility (ADF), the ADvanced Space Experiment Processor (ADSEP), and soon the ACT, will enable Techshot to serve more researchers and offer more diversified services on ISS. In combination, this broad range of services is expected to improve Techshot's competitive position. Furthermore, with the expected availability of commercial launch vehicles (e.g. SpaceX, Orbital), once these vehicles begin routine visits to the ISS, and eventually to commercial space stations (e.g. Bigelow) and free fliers (e.g. DragonLab), the economics of transporting and processing materials in microgravity should become far more compelling. And eventually, given enough commercial launch vehicle capacity, ACT could become the fluid transfer tool of choice to support the processing of larger quantities of high-value materials, including cells, pharmaceuticals and other high-value medical-grade materials. Finally, the potential also exists for an ACT patent and licensing to companies interested in selling such a product to ground-based research labs for use in BSL-3 facilities where additional containment of hazardous biological materials is critical for employee safety.